1 Renal-Electrolyte and Hypertension Division of the University of Pennsylvania, Philadelphia, PA, 3 Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 2 Cellular Biology Unit, Department of Biology, Universidad Autónoma de Madrid, Spain and 4 Klinik für Innere Medizin III, University of Jena, Jena, Germany
Correspondence and offprint requests to: Sheldon Chen, MD, 700 Clinical Research Building, 415 Curie Boulevard, Philadelphia, PA 19104-4218, USA. Email: chens{at}mail.med.upenn.edu
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods. Cultured mouse podocytes were treated with various doses of AngII for selected periods of time, with or without inhibitors of TGF-ß and VEGF signalling, SB-431542 and SU5416, respectively. TGF-ß1 and VEGF were assayed by enzyme-linked immunosorbent assay (ELISA); 3(IV) collagen, TGF-ß type II receptor and phospho-Smad2 were assayed by immunoblotting.
Results. AngII 1010 M was found to stimulate the production of
3(IV) collagen significantly in as short a time as 3 h. The expression of
3(IV) collagen was influenced by the TGF-ß system, but AngII did not increase the podocyte's production of TGF-ß1 ligand; rather, it increased the expression of the TGF-ß type II receptor and activated the TGF-ß signalling system through Smad2. Despite the TGF-ß receptor upregulation, synergy between AngII and TGF-ß1 to boost
3(IV) collagen production was not observed. However, blockade of TGF-ß signalling with SB-431542 prevented AngII from stimulating
3(IV) collagen production. Podocyte expression of
3(IV) collagen was also increased by the autocrine activity of VEGF. Podocytes were stimulated to secrete VEGF by 1010 M or higher AngII after 48 h. Blockade of the endogenous VEGF activity by SU5416 prevented AngII-stimulated
3(IV) collagen production.
Conclusions. AngII stimulates the podocyte to produce 3(IV) collagen protein via mechanisms involving TGF-ß and VEGF signalling. Alterations in
3(IV) collagen production may contribute to GBM thickening and perhaps proteinuria in diabetes.
Keywords: GBM thickening; proteinuria; SB-431542; Smad2; SU5416; TGF-ß type II receptor
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Located at the periphery of each glomerular capillary loop, podocytes are bathed in an ultrafiltrate that is rich in AngII. In addition, these cells possess both the AT1 and AT2 receptors that mediate almost all of the physiological actions of AngII [3]. One of the non-haemodynamic effects of AngII is to stimulate the production of extracellular matrix [2], which in the case of the podocyte could be one of the novel chains of type IV collagen, a principal building block of the glomerular basement membrane (GBM). In particular, the 3 chain of collagen IV was selected for further investigation, because immunohistochemical studies on diabetic renal tissue have found that the subepithelial zone of the GBM is enriched in
3 and
4(IV) collagen [4]. The GBM thickening that results may be associated with the degree of proteinuria in diabetes [5].
The expression of 3(IV) collagen in podocytes is stimulated by at least two effector cytokines. Treatment with exogenous transforming growth factor-ß1 (TGF-ß1) markedly increases the production of this collagen IV chain in cultured podocytes [6,7]. In addition, the TGF-ß signalling system mediates the stimulation of
3(IV) collagen production by high ambient glucose, perhaps due to upregulation of the TGF-ß type II receptor (TßRII) rather than the TGF-ß1 ligand [6]. When TGF-ß is blocked by antibody therapy in the diabetic mouse, the thickening of the GBM is partially reversed [8], consistent with TGF-ß playing an important role in the podocyte overexpression of GBM collagens such as
3(IV). Another cytokine that stimulates the production of
3(IV) collagen is vascular endothelial growth factor (VEGF). In cultured mouse podocytes, addition of exogenous VEGF164 increases
3(IV) protein, and inhibition of VEGF signalling by SU5416 (a pan-VEGF receptor inhibitor) prevents VEGF-stimulated
3(IV) collagen expression [7]. Furthermore, the endogenous VEGF that is constitutively secreted by the podocyte can act in an autocrine loop to sustain a basal level of
3(IV) production. This podocyte-derived VEGF is also responsible for part of TGF-ß's stimulatory effect on
3(IV) collagen production [7]. Since TGF-ß and VEGF activities can be stimulated by AngII [9,10], the intriguing possibility arises that these two cytokine systems may underlie certain effects of AngII on the podocyte.
The present study was undertaken to evaluate the impact of graded concentrations of AngII on the podocyte's production of a key GBM constituent, 3(IV) collagen. After evaluating the doseresponse and time course relationships between AngII treatment and
3(IV) collagen production, we tested whether the TGF-ß and VEGF systems might mediate AngII's effect on
3(IV) collagen. First, components of the TGF-ß signalling system were analysed in terms of their response to AngII treatment, and then the TGF-ß pathway was specifically inhibited to gauge its involvement in AngII-stimulated
3(IV) collagen production. Because TGF-ß1 itself increases
3(IV) collagen expression, a synergy between TGF-ß1 and AngII was investigated. Secondly, the effect of AngII on the podocyte secretion of VEGF was characterized. Specific blockade of the VEGF signalling pathway was used to determine the role of the VEGF autocrine loop in mediating the stimulatory action of AngII on the production of
3(IV) collagen.
![]() |
Subjects and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Experimental treatment conditions
Differentiated podocytes were treated with exogenous AngII (Sigma, St Louis, MO) in concentrations ranging from 1012 to 105 M. Treatment times ranged from 1 to 8 h if the experiment was conducted in a regular working day and up to 52 h if conducted over several days (see figure legends for details). Because AngII is degraded within 2 h when in contact with the cultured podocytes (by cell surface aminopeptidases [12]), the dose of AngII was replenished every 2 h during the working day; for experiments longer than a single working day, the AngII dose was replenished every 2 h during an 8 h working day, and then dosing was resumed in the morning of the subsequent working day.
In the AngII/TGF-ß1 synergy experiment, recombinant human TGF-ß1 (R&D Systems) was added at 2 ng/ml for 4 h. This dose and duration have been shown to significantly stimulate 3(IV) collagen production [6]. Concurrent with the AngII treatment in certain experiments, specific inhibitors of the TGF-ß and VEGF signalling pathways were added: SB-431542, an inhibitor of the TGF-ß type I receptor kinase (gift of Dr Nicholas Laping, GlaxoSmithKline; IC50
100 nM) [6], and SU5416, an inhibitor of the VEGF receptor tyrosine kinases (gift of SUGEN/Pfizer; IC50
1 µM for inhibition of receptor autophosphorylation) [7].
Western immunoblotting
Preparation of total lysate protein in RIPA buffer followed by SDSPAGE (38% gradient, pre-cast gels from NuPAGE; Invitrogen, Carlsbad, CA) and wet transfer to a nitrocellulose membrane (Bio-Rad, Hercules, CA) were performed as described [6]. The membrane was blocked in 5% non-fat milk in Tris-buffered saline0.1% Tween-20 (TBS-T) and probed overnight at 4°C with one of the following primary antibodies: human anti-3(IV) collagen (University of Pennsylvania), rabbit anti-TßRII (Santa Cruz Biotechnology), rabbit anti-phospho-Smad2 (Cell Signaling Technology) or mouse anti-ß-actin antibody (Sigma). After three washes in TBS-T, membranes were probed with the appropriate secondary antibody: goat anti-human (Jackson ImmunoResearch, West Grove, PA), donkey anti-rabbit (Amersham Biosciences, Piscataway, NJ) or sheep anti-mouse antibody (Amersham), each conjugated to horseradish peroxidase (HRP). The HRP-catalysed chemiluminescence reaction was developed with SuperSignal West Pico substrate (Pierce Biotechnology, Rockford, IL), allowing the detection of immunoreactive protein bands. The membrane was re-probed with ß-actin to correct for small differences in loading. The resulting bands on film were quantitated by computer-assisted video densitometry. Using the ImageJ 1.29x software (National Institutes of Health, Bethesda, MD), the protein band density was measured. The amount of protein under control conditions was assigned a relative value of 100%.
TGF-ß1 ELISA
Conditioned cell culture media were frozen at 20°C until assayed by a TGF-ß1 ELISA kit, performed according to the manufacturer's instructions (R&D Systems). In brief, the supernatants of the podocyte cultures were acid activated with 1 M HCl and then neutralized with 1.2 M NaOH/0.5 M HEPES to measure total TGF-ß1 (latent plus active fractions). Samples were applied to microtitre plates that had been pre-coated with TßRII. After a 3 h incubation, the wells were washed and a HRP-conjugated anti-TGF-ß1 antibody was added to the wells for 1.5 h at room temperature. Following another wash, the substrate for HRP was added. The resulting chromogenic reaction was halted with a stop solution. The absorbance at 450 nm was measured in a microplate reader. TGF-ß1 concentrations were determined from the standard curve and corrected for the amount of total cell protein (data expressed as pg of TGF-ß1/mg of protein).
VEGF120,164 ELISA
Cell culture media supernatants were frozen at 20°C until assayed for VEGF using a commercial ELISA kit (R&D Systems). The supernatants were dispensed onto a microtitre plate coated with an anti-VEGF antibody that recognizes mouse VEGF120,164 and then sandwiched with a secondary anti-VEGF antibody conjugated to HRP. The resulting chromogenic reaction was stopped and read at 450 nm, and the concentration of VEGF was determined from the standard curve. VEGF concentrations were then corrected for the total protein concentrations, and the data were expressed as pg of VEGF/mg of protein.
Statistical analysis
Graphical data are displayed as the mean±SE for the number of independent experiments indicated in the figure legends. When comparing two independent sets of data, i.e. control vs an experimental group, the unpaired Student's t-test was used. When comparing control with multiple treatment conditions as in the doseresponse and time course data, a two-way analysis of variance (ANOVA) with Bonferroni post-test was used. P<0.05 was considered statistically significant.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
AngII does not stimulate TGF-ß1 secretion
Treatment with AngII doses, increasing in exponential orders of magnitude from 1012 to 105 M, did not significantly raise the level of total TGF-ß1 protein secreted into the cell culture media of mouse podocytes over an 8 h span (Figure 2A, left panel). Likewise, a fixed dose of 108 M AngII used for selected periods of time from 6 to 48 h failed to stimulate podocyte secretion of total TGF-ß1 into the media supernatant (Figure 2A, right panel).
|
AngII activates TGF-ß signalling
To demonstrate the functional significance of AngII-stimulated TßRII, evidence for the activation of the TGF-ß signalling pathway was sought. After binding to TßRII, TGF-ß signals primarily through the Smad2 and Smad3 pathways [13]. Activation of either pathway can be assessed by the phosphorylation of the Smad2 or Smad3 protein. Levels of phospho-Smad2 significantly increased by 55±13% with the addition of 108 M AngII for 8 h (Figure 2C). However, phosphorylation of Smad2 was blocked by an inhibitor of TGF-ß signalling, SB-431542 (1 µM for 8 h), such that steady-state levels of phospho-Smad2 were suppressed below baseline (Figure 2C). In the presence of SB-431542, AngII could not stimulate Smad2 phosphorylation (Figure 2C).
TGF-ß signalling mediates the effect of AngII on 3(IV) collagen
Consistent with the doseresponse and time course data, AngII treatment at 108 M for 8 h increased 3(IV) collagen production by
30% (P<0.05 vs control, Figure 3). However, AngII-stimulated
3(IV) collagen production was prevented by pre-treatment with SB-431542 (1 µM for 8 h). This small molecule inhibitor blocks the kinase activity of TßRI, arresting the transmission of the TGF-ß signal. Thus, the TGF-ß pathway plays a role in the mechanism of AngII-stimulated production of
3(IV) collagen.
|
|
|
VEGF signalling system mediates AngII-stimulated 3(IV) collagen production
Because of the doseresponse and time course characteristics of the AngII effect on VEGF production, cultured podocytes were treated with 106 M AngII for 52 h to ensure an increased ambient VEGF level. This podocyte-derived VEGF acts in an autocrine loop to stimulate the production of 3(IV) collagen [7]. Using this as an end-point, AngII stimulated the protein production of
3(IV) collagen by 37% (Figure 6). However, AngII's effect on
3(IV) collagen was completely prevented by an inhibitor of VEGF signalling, SU5416 (Figure 6) [7].
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Given the profibrotic nature of AngII in most of the renal cell types studied to date, it is reasonable to evaluate the effects of AngII on the podocyte's expression of extracellular matrix. Perhaps the most suitable set of matrix proteins to assay would be type IV collagen, because this branching, sheet-like collagen forms the meshwork of the GBM. Specifically, we assayed the novel 3 chain of type IV collagen because it is synthesized by the podocyte, and its relative abundance increases in the thickened GBM of diabetic nephropathy [17]. The expression of
3(IV) collagen previously was shown to be increased by AngII, but these experiments were performed in proximal tubule cells [18]. In our podocyte studies, AngII was found to stimulate
3(IV) collagen production significantly at 1011 M, but the biologically significant effect seems to occurs at 1010 M AngII and above (Figure 1).
The expression of 3(IV) collagen in mouse podocytes is potently stimulated by TGF-ß1 treatment [6]. We investigated whether the TGF-ß system might play a role in AngII-stimulated
3(IV) collagen production. AngII did not significantly stimulate TGF-ß1 secretion into the culture media, but AngII did stimulate the expression of TßRII (Figure 2B). Perhaps because it upregulated TßRII, AngII was able to activate the TGF-ß signalling system in podocytes, manifested by the increased phosphorylation of Smad2 that was preventable by a TGF-ß signalling inhibitor, SB-431542 (Figure 2C). In this regard, the podocyte differs from other renal cell types that respond to AngII by increasing their expression of both TGF-ß ligand and type II receptor [19].
One consequence of AngII stimulating the TGF-ß system appears to be an increase in 3(IV) collagen production. The ability of AngII to augment
3(IV) collagen production was abrogated by specifically inhibiting the TGF-ß type I receptor (Figure 3), through which TGF-ß and TßRII ultimately signal. This indicates that the effect of AngII to stimulate
3(IV) collagen production is mediated by the TGF-ß system. That treatment with SB-431542 alone significantly decreased
3(IV) collagen levels suggests that the basal rate of
3(IV) production is dependent upon endogenous TGF-ß activity (Figure 3).
Another consequence of AngII-induced expression of TßRII could be a kind of synergy between AngII and TGF-ß1. AngII stimulates 3(IV) collagen production in a TGF-ß-dependent manner, but, by increasing the abundance of the TßRII, AngII may potentiate the effect of the ambient TGF-ß. As expected, both AngII and TGF-ß1 by themselves increased
3(IV) collagen levels, but the combination of AngII and TGF-ß1 did not significantly raise
3(IV) collagen production above that found with TGF-ß1 alone (Figure 4). Care was taken to allow the AngII-treated podocytes enough time to upregulate the production of TßRII, and afterwards to treat the podocytes with a low, submaximal dose of TGF-ß1 (0.5 ng/ml) to allow the
3(IV) collagen level to increase if possible. Our results currently argue against a synergism between AngII and TGF-ß1 treatments on the podocyte production of
3(IV) collagen.
Collagen IV expression in podocytes is also influenced by the endogenous VEGF system. This podocyte-derived VEGF recently has been discovered to act in an autocrine manner to exert profound physiological and pathophysiological effects in podocytes [7,20]. Lending credence to these observations, podocytes are known to possess certain receptors for VEGF, including VEGFR-1 (Flt-1), VEGFR-3 (Flt-4) and the accessory VEGF receptorneuropilin-1 [7,20]. The VEGF autocrine loop in podocytes appears to function in intracellular calcium release and protection against cytotoxicity and apoptosis [20]. In addition, our laboratory has found that the VEGF autocrine loop plays an important role in the podocyte's expression of 3(IV) collagen [7]. Under standard conditions, the actions of endogenous VEGF maintain a basal level of
3(IV) collagen production, but supraphysiological doses of VEGF can augment
3(IV) expression [7]. Finally, podocyte-derived VEGF is stimulated by TGF-ß1, and the ensuing increase in VEGF autocrine activity mediates part of TGF-ß1's ability to stimulate
3(IV) collagen production [7].
The endogenous VEGF system may also mediate the effect of AngII to stimulate 3(IV) collagen expression. Podocyte VEGF secretion is increased by doses of AngII at 1010 M or higher (Figure 5A) but, interestingly, VEGF production is actually decreased by AngII at 24 h (Figure 5B). Afterwards, continued treatment with AngII causes the VEGF production to catch up to control levels at 30 h and to surpass them at 48 h (Figure 5B). Given the time course relationship between AngII and VEGF, AngII may increase
3(IV) collagen expression at 48 h or later. We found that AngII stimulates
3(IV) protein production at 52 h, and this is prevented by an inhibitor of VEGF signalling, SU5416 (Figure 6). Together with the data from Figure 3, the findings suggest that the early effect of AngII on
3(IV) collagen is TGF-ß dependent and that the late effect is VEGF dependent.
Ultimately, the impact of AngII on podocyte pathobiology with regard to diabetic nephropathy may lie in the alteration of 3(IV) collagen production. The absolute increase in this
collagen chain may help to explain the GBM thickening of diabetes [17], a kidney lesion that can be prevented by AngII antagonists. Despite the increase in the quantity of GBM, the quality of GBM seems to suffer, because the thickened GBM loses its permselectivity and becomes more permeable to filtered proteins, most notably albumin. It is intriguing to postulate that the underlying basis may involve an alteration in the ratio of
3(IV) collagen to the other
chains that disrupts the podocyte's methodical assembly of the GBM. Consistent with this theory, the GBM in diabetes is enriched in
3 and
4(IV) collagen but relatively deficient in
5(IV) collagen [17]. According to our study, the disproportionate increase in the podocyte production of
3(IV) collagen may derive from the actions of AngII. Insofar as alterations in
3(IV) collagen contribute to GBM thickening and perhaps proteinuria in diabetes, a mechanism underlying the renoprotection by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be to shield the podocyte from the metabolic effect of AngII to activate the TGF-ß and VEGF systems that transmit the signal to stimulate
3(IV) collagen production, highlighting the complex interplay between the three major cytokine systems paramount to podocyte biology in diabetes.
![]() |
Acknowledgments |
---|
Conflict of interest statement. None declared.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|